This inventor holds 2 USPTO granted patents. Top assignee: Yamanouchi Pharmaceutical Company Ltd.. Active years: 2001-2003.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2001-2003
Title: The Innovative Contributions of Itsuro Shimada
Introduction
Itsuro Shimada is a notable inventor based in Ibaraki, Japan. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that target central nervous system disorders. With a total of 2 patents to his name, Shimada's work is recognized for its potential therapeutic applications.
Latest Patents
Shimada's latest patents include innovative compounds such as thiazolobenzoimidazole derivatives and tricyclic pyrrole or pyrazole derivatives. The tricyclic pyrrole or pyrazole derivative is represented by a specific general formula and is noted for its strong affinity and selectivity for the 5-HT receptor. This compound shows promise for treating various central nervous system diseases, including sexual disorders, eating disorders, anxiety, depression, and sleeping disorders.
Career Highlights
Throughout his career, Itsuro Shimada has been associated with Yamanouchi Pharmaceutical Company Ltd., where he has contributed to groundbreaking research and development in the pharmaceutical industry. His work has been instrumental in advancing the understanding of drug interactions and therapeutic potentials.
Collaborations
Shimada has collaborated with esteemed colleagues such as Kyoichi Maeno and Shuichi Sakamoto. These partnerships have fostered a collaborative environment that enhances innovation and the development of new therapeutic solutions.
Conclusion
In summary, Itsuro Shimada's contributions to pharmaceutical innovations are noteworthy. His patents reflect a commitment to addressing critical health issues through scientific research and development. His work continues to inspire advancements in the treatment of central nervous system disorders.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile